

FULL-LENGTH ORIGINAL RESEARCH

Safety and effectiveness of stereotactic laser ablation for epileptogenic cerebral cavernous malformations

Jon T. Willie^{1,2}  | James G. Malcolm¹ | Matthew A. Stern³  | Lindsay O. Lowder⁴ | Stewart G. Neill⁴ | Brian T. Cabaniss² | Daniel L. Drane^{2,5,6} | Robert E. Gross^{1,2}

¹Department of Neurological Surgery, Emory University School of Medicine, Atlanta, Georgia

²Department of Neurology, Emory University School of Medicine, Atlanta, Georgia

³Medical Scientist Training Program, Emory University School of Medicine, Atlanta, Georgia

⁴Department of Pathology, Emory University School of Medicine, Atlanta, Georgia

⁵Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia

⁶Department of Neurology, University of Washington School of Medicine, Seattle, Washington

Correspondence

Jon T. Willie or Robert E. Gross, Department of Neurosurgery, Emory University, Atlanta, GA.
Emails: jon.t.willie@emory.edu or rgross@emory.edu

Funding information

National Institute of Neurological Disorders and Stroke, Grant/Award Number: 1@10OD016413-01, K02NS070960, R01NS088748; Medtronic, Inc., Grant/Award Number: A1225797BFN:1056035; , Grant/Award Number: A1225797BFN:1056035

Summary

Objective: Magnetic resonance (MR) thermography-guided laser interstitial thermal therapy, or stereotactic laser ablation (SLA), is a minimally invasive alternative to open surgery for focal epilepsy caused by cerebral cavernous malformations (CCMs). We examined the safety and effectiveness of SLA of epileptogenic CCMs.

Methods: We retrospectively analyzed 19 consecutive patients who presented with focal seizures associated with a CCM. Each patient underwent SLA of the CCM and adjacent cortex followed by standard clinical and imaging follow-up.

Results: All but one patient had chronic medically refractory epilepsy (median duration 8 years, range 0.5–52 years). Lesions were located in the temporal (13), frontal (five), and parietal (one) lobes. CCMs induced magnetic susceptibility artifacts during thermometry, but perilesional cortex was easily visualized. Fourteen of 17 patients (82%) with >12 months of follow-up achieved Engel class I outcomes, of which 10 (59%) were Engel class IA. Two patients who were not seizure-free from SLA alone became so following intracranial electrode-guided open resection. Delayed postsurgical imaging validated CCM involution (median 83% volume reduction) and ablation of surrounding cortex. Histopathologic examination of one previously ablated CCM following open surgery confirmed obliteration. SLA caused no detectable hemorrhages. Two symptomatic neurologic deficits (visual and motor) were predictable, and neither was permanently disabling.

Significance: In a consecutive retrospective series, MR thermography-guided SLA was an effective alternative to open surgery for epileptogenic CCM. The approach was free of hemorrhagic complications, and clinically significant neurologic deficits were predictable. SLA presents no barrier to subsequent open surgery when needed.

KEYWORDS

cerebral cavernous malformation, laser interstitial thermal therapy, lesional epilepsy, magnetic resonance thermometry, seizure, stereotactic laser ablation

1 | INTRODUCTION

Cerebral cavernous malformations (CCMs) are abnormal vascular lesions within the central nervous system, the

growth or hemorrhage of which may be associated with headaches, seizures, and neurologic deficits.^{1,2} Structurally, CCMs are intertwined, “mulberry-like” clusters of thin-walled vessels lined by endothelial cells, without intervening brain parenchyma, and are associated with developmental venous anomalies. On T2-weighted magnetic resonance

Willie and Malcolm contributing equally to the manuscript.

imaging (MRI), CCMs appear heterogeneously hyperintense with a surrounding hypointense rim of hemosiderin-laden parenchyma. CCMs are relatively common (incidence of 0.16%³) and carry a 5-year symptomatic hemorrhage risk of 15.8%.⁴⁻⁷ CCMs cause gliosis and neuronal irritation^{8,9}; up to 70% of patients with supratentorial CCMs present with seizures, and 40%-50% of these cases become medically refractory.^{2,10,11}

Surgical resection of a CCM and surrounding cortex is considered critical to achieving seizure freedom.⁴⁻⁶ Stereotactic laser ablation (SLA) using coagulates tissue at 50°C-90°C while making use of real-time MR thermography to visualize collateral structures to be protected.^{12,13} SLA provides an alternative to open epilepsy surgery for a variety of brain pathologies,¹³⁻¹⁹ and provides neurocognitive outcomes superior to those of traditional open resection for medial temporal lobe epilepsy.²⁰⁻²²

We previously described the technical feasibility of SLA of CCMs.²³ Herein we report the safety, clinical effects, and imaging features of 19 patients who underwent SLA of CCMs, and an example of postablation histopathologic findings.

2 | METHODS

2.1 | Patient selection

Following our first 5 successive patients,²³ additional patients underwent SLA between July 2012 and September 2018 at a single institution. Indication for surgery was the presence of a CCM causing drug-resistant seizures, except for Patient 6, who sought early intervention to discontinue antiepileptic medications.²⁴ Brain MRI in each case showed a characteristic “popcorn” appearance with a rim of hypointensity on T2-weighted sequences and prominent blooming artifact on susceptibility-weighted sequences indicating the presence of hemosiderin. In all but Patient 6, additional preoperative evaluation included neuropsychometric testing, long-term video-electroencephalography (EEG), and 18-fluorodeoxyglucose positron-emission tomography (FDG-PET). In addition, Patient 16, with a lesion in the dominant postcentral gyrus/sulcus, underwent functional MRI for language and stereo-EEG (SEEG) with cortical mapping by direct electrical stimulation. Patient 17, with a lesion in the nondominant precentral gyrus/sulcus, underwent functional MRI for motor localization and awake motor testing during ablation.

All patients elected to undergo laser ablation as the primary surgical intervention over open resection and signed informed surgical consent. The first 5 patients were told that application of SLA to CCM was novel, untested, and carried an uncertain risk of bleeding.²³ Thereafter, all patients were apprised of accruing evidence of safety from

Key Points

- Magnetic susceptibility of sequestered blood products within CCMs can compromise MR thermography within the boundaries of these lesions, but perilesional cortex is imaged with relative ease
- MR thermography-guided SLA is a potentially safe and effective surgical alternative to epileptogenic CCMs
- Although we observed no hemorrhages, SLA and open surgery should be used with caution in regions at risk of causing disability
- Interval imaging and pathologic examination suggest that SLA causes involution of CCMs
- SLA presents no barrier to subsequent intracranial monitoring or open resection

our initial experience. All patients were specifically warned that bleeding, unanticipated neurologic deficits, or need for additional surgery could occur. This retrospective review of clinical data for research was approved by the Emory University Institutional Review Board.

2.2 | Stereotactic surgical procedure

All patients underwent general anesthesia except for Patient 17, who was treated while awake. At the beginning of each procedure, patients were administered intravenous antibiotic for infection prophylaxis. Most were also administered intravenous dexamethasone, and many received levetiracetam. Ablations were performed by one of 2 surgeons (JTW or REG) using the Visualase Thermal Therapy System (Medtronic, Inc.), which utilizes laser energy (up to 15W, 980 nm) delivered through an optical fiber inside a saline-cooled cannula (1.65 mm outer diameter) to produce rapid and localized tissue injury.¹² For the minority of cases, we used a traditional stereotactic frame (Cosman-Roberts-Wells [CRW] stereotactic frame, Integra Neurosciences), with the Stealth S7 (Medtronic, Inc.) Framelink targeting software, with placement of the stereotactic bolt in the operating room followed by transport to the MR suite for treatment. For the majority of cases, we used the ClearPoint MRI-guided Neuro Navigation Platform (MRI Interventions), performing the entire procedure within an interventional MRI suite. The relative advantages of each workflow are detailed elsewhere.^{13,25}

In all cases, we performed final insertion of the device into the body of the CCM only with the patient positioned in the MRI scanner, followed by immediate imaging. The Visualase workstation analyzed real-time thermography to

predict cumulative tissue damage during the ablation. Postablation MRI, including diffusion-weighted, T2 inversion recovery, and contrast-enhanced T1 sequences confirmed total area of ablation. When the ClearPoint platform was used, a second ablation track was made to maximize the treatment area when judged important. Following each procedure, the device was completely removed, the surgical site closed with a dissolvable suture, general anesthesia was reversed, and the patient was extubated. Patients were admitted to a regular hospital ward until discharge. Patients were instructed to remain on antiepileptic medications and weaned at the discretion of a treating neurologist.

2.3 | Clinical follow-up and analysis

At each return visit, patients were queried as to the occurrence of seizures, any adverse effects, and medication status. A small minority provided follow-up by documented phone interviews with clinical staff. Seizure outcomes are reported using the Engel classification scheme.²⁶ All but Patients 18 and 19 had >12 months of follow-up after ablation. Patients not rendered free of disabling seizures by ablation alone were considered eligible for additional surgical procedures. Kaplan-Meier survival analysis was performed with respect to postoperative recurrence of any debilitating seizure occurring more than 4 weeks postablation (consistent with the Engel classification scheme), and censorship occurred at each subject's last follow-up.

2.4 | Image follow-up and processing

Volumes were calculated using OsiriX (Pixmeo) by tracing contours in each slice along the dimension of the thinnest cut. Preablation CCM volumes were measured using the T2-weighted MRI, tracing hypointense hemosiderin rims. Immediate postablation volumes were measured by tracing the enhancing borders of gadolinium-contrasted T1-weighted images (thermal injury zone). At last available follow-up imaging, the residual CCM volume was traced around the hypointense residual nodule on T2-weighted MRI.

2.5 | Pathologic examination

Patients 3 and 16 underwent open resection after ablation. Although the ablation from Patient 3 was not identified, a nodular structure corresponding to the ablated CCM from Patient 16 was resected, fixed in formalin, embedded in paraffin, sectioned at 4 μ m, and stained with hematoxylin and eosin (H&E). Immunohistochemistry was performed using antisera directed against glial fibrillary acidic protein

(GFAP; Dako; Polyclonal, no dilution) and MIB1/Ki67 (Dako; MIB-1 1:80 dilution).

3 | RESULTS

3.1 | Preoperative characteristics

We performed SLA on 19 sequential patients (9 female) presenting with focal (motor or cognitive) seizures with or without progression to secondary tonic-clonic activity and a clinically correlating CCM (Table 1, Figures 1-3). The median preoperative epilepsy duration was 8 (range 0.5-52) years, and the mean age at surgery was 40.4 (standard deviation [SD] \pm 17.2, range 16-76) years. Lesion locations included temporal (13), frontal (5), and parietal (1) lobes. All but Patient 6 (who sought early intervention to discontinue seizure medications) met strict criteria for medically refractory epilepsy.²⁷ Two patients had prior interventions at outside institutions (stereotactic radiosurgery in Patient 8, and vagus nerve stimulation for unclear indications in Patients 8 and 11). Patient 16 underwent intracranial monitoring (SEEG) at our institution for unsatisfactory concordance of noninvasive studies prior to SLA.

3.2 | Stereotactic laser ablation

Table 2 details each surgical approach, and Figures 1-3 show each ablation, with Figures 1 (Patient 6) and 3 (Patient 16) providing additional details. The laser apparatus was placed via a CRW frame and stereotactic bolt in 3 cases. The remaining 16 cases were performed entirely within an interventional MRI suite with a disposable MR guidance frame (ClearPoint). In all cases, we successfully placed the laser applicator and ablated the tissue volume encompassing the CCM and surrounding parenchyma. For Patients 12 and 16, a second trajectory was used to extend ablation of hemosiderin-laden cortex. For Patient 18, a second trajectory provided additional ablation of associated mesial temporal sclerosis.

We found that because of the paramagnetic effects of concentrated blood products within CCMs, intraoperative thermal (gradient echo) imaging had signal dropout within the boundaries of larger lesions, thus delaying the real-time estimation of irreversible damage (Figures 1E-F and 3B-C). However, since the perilesional cortex surrounding each CCM imaged normally, overall monitoring of the extent of the intended ablation was executed without technical difficulty. Immediate postablation T2 fluid-attenuated inversion recovery (FLAIR), diffusion-weighted imaging (DWI), and postcontrast T1-weighted sequences verified intended ablations (Figures 1-3).

TABLE 1 Preoperative patient and lesion characteristics

Patient no.	Sex	Age at surgery (y)	Epilepsy duration (y)	Baseline seizure type (ILAE classification ²⁴)	Baseline AEDs	Prior procedure	Location	Associated vascular structures
1	M	37	8	Focal impaired awareness	LAC, LAM	-	L Temporal (FG)	Tentorial edge
2	M	29	5	Focal aware and focal impaired awareness \pm to bilateral tonic-clonic	LEV, OXC, TOP	-	R Temporal (Hc, unc, apex)	PCA (ATA)
3	F	67	46	Focal aware and focal impaired awareness \pm to bilateral tonic-clonic	CLOB, LEV, ZON	-	R Frontal (MFG)	Small DVA
4	M	66	20	Focal aware cognitive \pm to bilateral tonic-clonic	LEV	-	L Temporal (FG & ITG)	DVA and tentorial edge
5	F	76	52	Focal impaired awareness \pm to bilateral tonic-clonic	GAB, PRI	-	L Temporal (posterior ITG)	DVA and vein of Labbé
6	F	34	0.5	Focal to bilateral tonic-clonic	LAM	-	R Frontal (MOG)	DVA to sphenoparietal sinus
7	F	40	8	Focal impaired awareness	LAC	-	R Temporal (Hc, unc, apex)	AChA (choroid fissure)
8	F	37	5	Focal impaired awareness \pm to bilateral tonic-clonic	LAC, LAM	SRS, VNS	R Temporal (pole)	DVA to sphenoparietal sinus
9	M	21	6	Focal to bilateral tonic-clonic (comorbid PNES)	LAM, LEV	-	R Temporal (pole)	DVA to sphenoparietal sinus
10	M	21	8	Focal impaired awareness	CLON, DIV, LAM	-	L Temporal (anterior perirhinal cortex)	Tentorial edge
11	M	16	5	Focal impaired awareness	LAM, LEV, OXC	VNS	L Temporal (Hc, posterior body)	Large DVA and AChA (choroid fissure)
12	F	31	13	Focal impaired awareness \pm to bilateral tonic-clonic	LAC, LAM	-	R Temporal (anterior ITG)	DVA to sphenoparietal sinus
13	M	19	7	Focal aware clonic	CLOB, LAM, OXC	-	L Frontal (PrCG)	Small DVA to vein of Trolard
14	F	56	7	Focal impaired awareness \pm to bilateral tonic-clonic	LEV, OXC	-	L Temporal (posterior ITG)	DVA and vein of Labbé
15	M	33	6	Focal to bilateral tonic-clonic	GAP, TOP	-	R Frontal (MFG)	Small DVA
16	F	50	21	Predominantly nocturnal focal impaired awareness	LAC, LEV, ZON	SEEG	L Parietal (PoCG, SMG)	Small DVA to superficial MCV
17	M	36	11	Focal aware motor seizure	LAC, LEV	-	R Frontal (PrCG)	Small DVA to vein of Trolard
18	M	62	14	Focal impaired awareness	LAC, LEV	-	L Temporal (entorhinal region) + MTS	AChA (choroid fissure)
19	F	36	2	Focal impaired awareness \pm to bilateral tonic-clonic	LAC, ZON	-	L Temporal (Hc, posterior body)	DVA to choroid fissure

ILAE, International League Against Epilepsy operational classification of seizure types.²⁴

AChA, anterior choroidal artery; AED, antiepileptic drug; ATA, anterior temporal artery; CLOB, clobazam; CLON, clonazepam; DIV, divalproate; DVA, developmental venous anomaly; FG, fusiform gyrus; GAB, gabapentin; Hc, hippocampus; ITG, inferior temporal gyrus; LAC, lacosamide; LAM, lamotrigine; LEV, levetiracetam; MCV, middle cerebral vein; MFG, middle frontal gyrus; MOG, medial orbital gyrus; MTS, mesial temporal sclerosis; OXC, oxcarbazepine; PCA, posterior choroidal artery; PNES, psychogenic nonepileptic seizures; PoCG, postcentral gyrus; PrCG, precentral gyrus; PRI, primidone; SEEG, stereo-electroencephalography; SMG, supramarginal gyrus; PCA, posterior cerebral artery; SRS, stereotactic radiosurgery; TOP, topiramate; VNS, vagus nerve stimulation; ZON, zonisamide.




FIGURE 1 Stereotactic laser ablation (SLA) of cerebral cavernous malformations (CCMs) in Patient 6. A, Preoperative axial T2 showing a CCM in the right medial orbital frontal gyrus (arrow). B, Preoperative axial gradient echo (GRE) image demonstrating blood products within the CCM. C, Preoperative postcontrast axial T1 showing minimal early enhancement of the CCM. D, Intraoperative delayed-contrast coronal T1 showing cannula placement within the CCM, without evidence of new bleeding or mass effect. E, Intraoperative screenshot from a Visualase workstation showing a live thermal map overlaid on a sagittal T2 image during ablation. Note some central signal dropout of gradient echo-based thermal imaging from static blood products. F, Intraoperative screenshot from a Visualase workstation showing a live cumulative irreversible damage estimate (orange pixels) overlaid on sagittal T2 during ablation. Note the damage at the brain-lesion interface. (G,H) Immediate postablation postcontrast coronal and axial T1 demonstrates the actual extent of ablation. I, Delayed axial T2 at 14 months postablation demonstrates a small hypointense involuting CCM surrounded by a hyperintense ablation cavity

3.3 | Adverse events

We observed no hemorrhagic complications following initial cannula insertion to target depth, during ablation, or following withdrawal of the laser cannula (Table 2). Moreover, no hemorrhagic complications resulted from additional trajectories in three patients (Patients 12, 16, and 18). Seventeen of 19 patients were discharged on the first postoperative day, with 2 (Patients 4 and 5) being discharged on the second day.

In Patient 11, the ablation of a CCM in the posterior hippocampus also extended into the temporal lobe white matter. This ablation caused a partial right superior quadrantanopia, likely due to injury of the optic radiation (Meyer's loop). This deficit was not disabling, as the patient recovered subjectively and subsequently obtained a license to drive. Patient 17, who underwent awake ablation in order to monitor motor function, began to develop intrinsic weakness of the nondominant hand, and ablation was then discontinued, in a manner analogous to the accepted approach for awake open surgery in eloquent cortex. The patient underwent occupational therapy, returned to work as a practicing dentist within 1 week, and denied

any functional disability at 12 months of follow-up. Patient 16 had no subjective deficits following ablation, but did sustain expected perioral sensory disturbance from open resection of the lateral postcentral gyrus, which has been persistent but nondisabling.

There were no readmissions related to surgery or seizures, and no other delayed complications were identified. Neuropsychological outcomes of laser ablation across different brain regions, collected in a subset of patients that chose to participate in a prospective research study with an independent consent process, will be the subject of future investigation.

3.4 | Seizure outcomes

Follow-up was obtained for a mean 30.6 ± 12.6 SD months (median 32, range 2-49, Table 2). Kaplan-Meier analysis revealed no seizure recurrence beyond 6 months after the perioperative period in the first 17 patients having >12 months follow-up (Figure 4A). Two patients each had a single seizure (Patient 5 at 6 months and Patient 11 at 2 months), but ultimately achieved Engel class IC status by remaining seizure-free for at least 2 years thereafter. At last

follow-up, 14 of 17 patients (82%) were free of disabling seizures from ablation alone (Engel class I) with 10 (59%) having been completely seizure-free from the time of surgery (Engel class 1A)(Figure 4B). In addition, 9 of 16 patients with >24 months follow-up (56%) were prescribed a reduced number of medications and 5 (31%) were off all antiepileptic medications at last follow-up (Tables 1 and 2). Patients 18 and 19 were not assigned an Engel classification due to short follow-up postablation.

Patients 3, 8, and 16 failed to achieve freedom from disabling seizures after ablation alone (Table 2). Patient 8 is classified as Engel class IIIA but has since been completely free of seizures for the last year after medication adjustment. Patient 3 (Figure 2, panel 3) had no period of meaningful seizure control and underwent open subdural electrode grid placement and ictal electrocorticography-guided right frontal topectomy at 9 months postablation, achieving 2 years of subsequent seizure freedom (Engel IA). Likewise, Patient 16 (Figure 3) had recurrent nocturnal seizures at 6 months

postablation (Table 2) and sought further surgical management. She underwent open subdural electrode grid placement and ictal electrocorticography-guided topectomy of the inferior postcentral gyrus (in which the site of her prior CCM ablation was identified, Figure 3F). This caused continuous perioral/tongue dysesthesia that was not disabling, and she remained completely seizure-free at 12 months after resection.

3.5 | Imaging outcomes

Lesions were in proximity to either an apparent developmental venous anomaly (14/19) or to another contrast-enhancing vessel or pial/dural interface (5/19)(Table 1). The mean preoperative volume of CCMs in this series was $0.7 \pm 0.6 \text{ cm}^3$ (range 0.1-2.5 cm^3), whereas immediate postablative contrasted T1-weighted images showed a mean ablation zone of $3.8 \pm 2.6 \text{ cm}^3$ (range 0.6-10.0 cm^3)(Table 2, Figures 1-3). Of the patients with follow-up imaging (14/19) at a mean




FIGURE 2 Imaging of cerebral cavernous malformations (CCMs) before and after stereotactic laser ablation (SLA). For each patient image set, preoperative T2, intraoperative immediate postablation postcontrast T1, and delayed postoperative T2 (when available) are shown. Numbers refer to patients in the clinical series (Patients 6 and 16 are presented in further detail in Figures 1 and 3, respectively). Yellow arrows point to preoperative lesion locations. (1) Coronal, left fusiform gyrus of temporal lobe. (2) Axial, uncus apex of hippocampus. (3) Coronal, right middle frontal gyrus. (4) Axial, left pes hippocampus. (5) Coronal, left posterior inferior temporal gyrus. (7) Axial, right uncus apex of hippocampus. (8) Coronal, right temporal pole. (9) Axial, right temporal pole. (10) Axial, right anterior perirhinal cortex. (11) Axial, left posterior hippocampus. (12) Coronal, right inferior temporal gyrus. (13) Axial, left precentral gyrus. (14) Coronal, left posterior inferior temporal gyrus. (15) Coronal, right middle frontal gyrus. (17) Axial, right precentral gyrus. (18) Axial, left entorhinal cortex of uncus. (19) Coronal, left posterior hippocampus. In general, delayed postablation imaging reveals T2 hypointensity within the involuted CCM and surrounding T2 hyperintensity




FIGURE 3 Stereotactic laser ablation (SLA) and eventual resection of cerebral cavernous malformations (CCMs) in Patient 16 with pathologic comparison to a nonablated CCM from an unrelated patient. A, Preoperative coronal T2 image showing CCM just above the sylvian fissure in the postcentral sulcus. B, Visualase ablation screenshot showing thermal temperature map. C, Visualase ablation screenshot showing cumulative irreversible damage estimate (orange pixels). D, Contrasted T1 image showing final extent of ablation. E, Delayed postablation T2 image showing smaller hypointense CCM with surrounding hyperintense ablation cavity. F, Operative photograph of ablated CCM (tan nodule, arrow) posterior to the precentral gyrus (M1) between the postcentral gyrus (S1) and supramarginal gyrus (SMG) and superior to the sylvian fissure (dotted black line) and superior temporal gyrus (STG). G, 100x microscopic appearance of Patient 16's CCM (H&E stain) showing postablation reactive type changes surrounding a large collapsed thickened vessel (perimeter approximated by dotted yellow outline and collapsed lumen lined by arrowheads). Scattered prior hemorrhage (arrows) and calcification (star) are evident within the thickened vessel wall. A small sclerotic hyalinized vessel (dotted black outline), an acute extravascular/extraparenchymal thrombus (T, likely a surgical artifact), and reactive brain parenchyma (asterisk) surround the collapsed vessel. H, For comparison, a surgically resected CCM from an unrelated patient shows multiple engorged, dilated vascular lumina (arrowheads) with thickened, hyalinized walls (arrows) without intervening brain parenchyma.

18 ± 10 (median 15, range 6-42) months postablation, we observed that ablated CCMs took on a nodular T2 hypointense appearance (Figures 1-3) and decreased volumes (Table 2, mean volume 0.2 ± 0.3 cm³). Involuting CCMs were surrounded by T2-hyperintense ablation cavities (encephalomalacia). Patient 17, with a CCM adjacent to primary motor cortex who underwent awake partial ablation, did not show encephalomalacia (Figure 2). We observed no delayed hemorrhages or unexpected postablation findings.

3.6 | Pathology

Patients 3 and 16 underwent additional open resection after laser ablation. In Patient 3, histopathologic examination of tissue resected from the epileptogenic zone, which included the prior ablation, revealed cortex with reactive gliosis, but without definitive features of a cavernous malformation. This absence may have resulted from insufficient sampling, or from prior complete obliteration of the relatively small lesion in this case. In Patient 16, the location of prior CCM (nodular tan-colored friable structure in Figure 3F, arrow) was grossly verified, dissected, and sent as an isolated specimen.

Microscopically, standard H&E staining of the specimen revealed postsurgical reactive type changes, but no definite residual/recurrent cavernous malformation. The sample contained primarily reactive astrogliosis, hemosiderin-laden macrophages (indicating prior hemorrhage), inflammatory infiltration, scattered calcifications, and areas of apparent fibrotic/sclerotic arachnoid mater (Figure 2G). Instead of dilated thin-walled vessels, we observed arachnoid tissue containing collapsed hyalinized vessels. Immunohistochemistry demonstrated both a low MIB1/Ki67 proliferation index (<1%) and a reactive gliosis, as highlighted by GFAP stain (not shown). For comparison, the typical microscopic features of a resected CCM from an unrelated, nonablated control patient shows dilated thin-walled vessels (Figure 2H). We interpret our findings to be consistent with obliteration of the presumed CCM.

4 | DISCUSSION

Recent studies have demonstrated the use of SLA in varied locations and pathologic entities associated with epilepsy,

TABLE 2 Operative approach and results

Patient no.	Stereotactic method ^a (surgeon)	Adverse events	LOS	Ablation volume (cm ³)	Absolute and relative change lesion volume (cm ³ and %) ^c	Imaging f/u (mo)	Clinical f/u (mo)	Seizure outcome after SLA (Engel class)	Seizure outcome after subsequent open surgery (Engel class)	Seizures postablation (if present)	AED status
1	CRW (REG)	None	1	1.0	0.3→0.03 (−90%)	22	41	IA	-	-	LAM (2→1)
2	ClearPoint (REG)	None	1	4.8	0.4→0.08 (−80%)	17	29	IB	-	Focal aware seizure at 4 mo postablation with medication withdrawal	LEV, OXC (3→2)
3	ClearPoint (REG)	None	1	1.9	0.2→0 (−100%)	7	42	IVA ^b	IA	Continued focal aware and focal impaired awareness seizures (less severe) until subsequent open surgery 9 mo postablation.	LEV (3→1)
4	ClearPoint (REG)	None	2	4.0	2.2→0.2 (−91%)	42	42	ID	-	Focal to bilateral tonic-clonic seizure at 9 mo with medication withdrawal and alcohol binge	CAR (1→1)
5	CRW (JTW)	None	2	4.6	0.6→0.3 (−50%)	21	32	IB	-	Focal aware seizures (brief nondisabling speech arrests) beginning at 6 mo postablation.	LAM, PRI (2→2)
6	ClearPoint (REG)	None	1	2.5	0.6→0.2 (−67%)	15	49	IA	-	-	None (1→0)
7	ClearPoint (REG)	None	1	4.8	0.5	-	44	IA	-	-	None (1→0)
8	ClearPoint (JTW)	None	1	2.6	1.0	-	38	IIIA	-	Focal impaired awareness ± bilateral tonic-clonic seizures ultimately controlled >1 y with medication adjustments	TOP, PHE (2→2)
9	ClearPoint (REG)	None	1	9.3	0.8→0.4 (−50%)	27	27	IA	-	Known comorbid PNES	LAM, LEV (2→2)
10	ClearPoint (JTW)	None	1	4.4	0.1→0.0 (−100%)	13	40	IA	-	-	None (3→0)
11	ClearPoint (REG)	Superior quadrantanopia (nondisabling).	1	7.0	0.9→0.1 (−89%)	32	32	IC	-	Focal impaired awareness seizure with missed medications at 2 mo postablation	None (3→0), VNS removed
12	ClearPoint2 trajectories (JTW)	None	1	10.0	1.2→0.1 (−92%)	14	30	IA	-	-	None (2→0)

(Continues)

TABLE 2 (Continued)

Patient no.	Stereotactic method ^a (surgeon)	Adverse events	LOS	Ablation volume (cm ³)	Absolute and relative change lesion volume (cm ³ and %) ^c	Imaging f/u (mo)	Clinical f/u (mo)	Seizure outcome after SLA (Engel class)	Seizure outcome after subsequent open surgery (Engel class)	Seizures postablation (if present)	AED status
13	ClearPoint (REG)	None	1	2.0	0.7→0.1 (−86%)	14	40	IA	-	-	None (3→0)
14	CRW (REG)	None	1	2.1	0.9→0.5 (−44%)	12	25	IA	-	-	LEV (2→1)
15	ClearPoint (REG)	None	1	1.1	0.1	-	26	IA	-	-	None (2→0)
16	ClearPoint2 trajectories (JTW)	None after laser. Dysesthesia after open surgery.	1	1.1	0.1→0.08 (−20%)	6	24	IID ^b	IA	Exclusively nocturnal focal impaired awareness seizures (lessfrequent recurred at 6 mo) until subsequent open surgery at 11 mo postablation	LAC, LEV, TOP (3→3)
17	ClearPoint (REG)	Hand weakness (fully recovered).	1	5.0	2.5→1.0 (−60%)	12	12	IA	-	-	LAC, LEV (2→2)
18	ClearPoint 2 trajectories (JTW)	None	1	3.5	0.2	-	3	-	-	Focal impaired awareness seizure at 2 wk postablation	LAC, LEV (2→2)
19	ClearPoint (REG)	None	1	0.6	0.4	-	2	-	-	-	LAC, ZON (2→2)

AED, antiepileptic drug; CAR, carbamazepine; CLOB, clobazam; f/u, follow-up; LAC, lacosamide; LAM, lamotrigine; LEV, levetiracetam; LOS, length of stay; OXC, oxcarbazepine; PHE, phenytoin; PNES, psychogenic nonepileptic seizures; PRI, primidone; TOP, topiramate; VNS, vagus nerve stimulation.

Engel Classification of epilepsy surgery outcomes: IA, Completely seizure-free since surgery; IB, Nondisabling simple partial seizures only since surgery; IC, Some disabling seizures after surgery, but free of disabling seizures for at least 2 years; ID, Generalized convulsions with antiepileptic drug withdrawal only; IIB, Rare disabling seizures since surgery; IID, Nocturnal seizures only; IIIA, worthwhile seizure reduction, IVA, no worthwhile seizure reduction.

^aStereotactic method utilized either traditional stereotactic Cosman-Roberts-Wells arc headframe (CRW, Integra, Inc.), or percutaneously mounted direct MRI guidance miniframe (ClearPoint System, MRI Interventions, Inc.). See Methods.

^bIn cases of early failure to maintain seizure freedom and transition to open surgery before 12 months, the outcome after laser ablation alone was imputed forward to operationally represent the lower Engel class at 12 months.

^cSecond absolute lesion volume and relative change are presented for the 14/19 cases for which follow-up imaging was available. For the remaining 5 cases, only preoperative lesion volume is presented.




FIGURE 4 Long-term seizure outcomes. A, Kaplan-Meier curve analysis depicts the proportion of patients having >12 month follow-up (Patients 1-17) who never experienced a disabling seizure following stereotactic laser ablation. No patient outcome deteriorated after 6 months. Dashed lines indicate the 95% confidence intervals. Tick marks indicate censorship. A vertical gray dotted line indicates the 24-month time point. B, Bar graph shows proportion (and numbers) of patient outcomes resulting from stereotactic laser ablation alone by Engel classification (I-IV). Only the 17 patients with >12 month outcome are presented (median last follow-up 32 months, range 12-49 months)

including medial temporal lobe epilepsy,^{13,21} focal cortical dysplasia,²⁸ tuberous sclerosis,²⁸ insular epilepsy,^{14,19} hypothalamic hamartomas,⁵ tumors,^{19,29-33} and periventricular nodular heterotopias.³⁴ CCMs, with their inherent vascularity and propensity toward recurrent hemorrhage, could be at greater risk of bleeding during stereotactic probe insertion and ablation. Nevertheless, certain empiric observations regarding CCMs suggest that the clinically significant bleeding risk associated with manipulating CCMs may be acceptably low. First, CCMs are made up of thin-walled vessels that are occult on arterial phase angiography due to low vascular pressure. Second, open surgical experience with resection of CCMs indicates that these lesions do not generally bleed if associated vessels are protected. Third, the natural history of CCMs may vary by location and genetic factors,³⁵ and our series selected for subjects presenting with epilepsy rather than symptomatic hemorrhage. Indeed, this series does not include any patient with a deep/brainstem lesion, thunderclap headaches, neurologic deficits, or familial cavernous malformations. Our previous technical report demonstrated the feasibility of stereotactic ablation of CCMs.²³ The present study of 19 patients with epilepsy further supports the relative safety of the approach, as hemorrhages were not observed, and neurologic deficits induced by ablation were expected for location and were ultimately nondisabling. Hospital lengths of stay were brief, and patients achieved a high rate of long-term seizure control.

4.1 | Comparison of SLA to other interventions

Ictal electrocorticography-guided resection of the CCM and surrounding cortex is considered the gold standard for

epilepsy management³⁵ yielding seizure control in 70%-80% of patients.^{4,36-42} Larger resections (ie, lobectomies) and frontal/insular locations have been associated with the best seizure outcomes.³⁶ However, microsurgery for CCMs requires an incision and craniotomy, risks unintended collateral injury (especially in deep or eloquent regions),³ and lobectomies induce wider neurocognitive deficits.²⁰⁻²²

Stereotactic radiosurgery (SRS) is an incisionless alternative to open surgery that yields rates of seizure freedom generally below those of open resection. In one large retrospective cohort, only 53% of patients were seizure-free ($n = 26/49$), and patients with more disabling complex partial seizures fared worse with respect to seizure control than did those with simple partial seizures.³⁹ SRS for CCM is also associated with a protracted temporal course and symptomatic radiation necrosis, especially at doses used to treat seizures.^{3,43-45}

By comparison, SLA is minimally invasive and immediately effective in most cases. Our high rate of seizure control (82% Engel class I) is comparable to that of open surgery, and in 2 patients (3 and 16) who were not initially rendered seizure-free, prior ablation proved to be no barrier to successful open surgery. Nor did prior interventions prevent ablation, as some patients had already undergone SRS and vagus nerve stimulation (VNS). Although neuropsychological outcomes were not detailed in this report, such results in a large number of ablations across diverse brain locations is the subject of a different study currently in preparation.

Although there were no hemorrhages, we observed 2 symptomatic neurologic deficits resulting from ablations, and another from a subsequent open resection. In Patient 11, a partial superior quadrantanopia resulted from ablating a posterior hippocampal CCM near the optic

radiation. Notably, any standard open approach to this lesion would likely transgress the optic radiation, and superior quadrantanopia is a known risk of standard open temporal lobe surgery. In our patient, this partial visual field deficit was nondisabling (noticed only when playing basketball), and he subsequently obtained a license to drive. In Patient 17, a neurologic deficit (increased non-dominant hand weakness) was an expected result of ablating a CCM in the precentral gyrus, and the ablation was carried out with the patient awake in order to monitor and minimize disability. He quickly returned to work as a dentist and reported complete functional recovery by 2 months. Notably, Patient 16 underwent awake open surgery and likewise sustained an expected deficit from resection in the lateral postcentral gyrus (nondisabling perioral sensory disturbance). Epilepsy surgery by any method is by nature destructive to cortex, and when performed in eloquent cortex, the chance for seizure freedom must be weighed against the risks of symptomatic neurologic deficits.

4.2 | Study limitations

Although this series includes all presenting cases of medically refractory epilepsy associated with a CCM at a high-volume epilepsy center over a 6-year period, it still represents a relatively small retrospective review of a non-homogeneous real-world cohort in which the outcome of any one patient will significantly affect group results. Nevertheless, our results align with the expected effectiveness of more extensive open microsurgery. Ideally, a larger series and a cohort design comparing SLA against gold standard open microsurgery would help evaluate the relative risks and benefits of SLA, but studies of this design have been prohibitively difficult to enroll, rendering statistical conclusions impractical.⁴⁴ Despite limitations, this series suggests relative safety and effectiveness of this procedure as a necessary first step toward future studies.

4.3 | Technical considerations

The Visualase Thermal Therapy System generates an ablation volume that is time- and power-dependent, and an ablation diameter may generally reach >2 cm if unlimited by anatomic boundaries such as pia or ventricles. In 3 patients, however, following completion of the initial ablation trajectory, the surgeon judged intraoperatively that the irregular size and shape of the target with its adjacent hemosiderin-laden cortex called for more extensive therapy. In these cases, use of an MRI-guidance platform (Clear-Point) facilitated redirection and execution of a second ablation trajectory during the same surgical session. SLA performed with other workflows utilizing a stereotactic bolt

provides less flexibility. In this setting, the surgeon may consider initial insertion of more than one bolt to support additional ablation trajectories.

Unlike other ablation targets, we observed that static blood products within CCMs can impair gradient echo-based thermography. The resulting signal dropout within portions of a CCM may degrade the thermal-anatomic correlation utilized to optimize safety. Thus, CCMs require additional vigilance, and the surgeon must rely more upon prior empirical experience with spatial-temporal ablation dynamics. Because temperatures within a CCM have greater potential for inaccuracy, additional care should be taken to use conservative laser power settings (eg, <12-13 W). Once ablation volume extends outside the CCM, thermal-anatomic correlation becomes more readily apparent, and thermography is sufficient for monitoring treatment of both perilesional epileptogenic cortex and off-target tissue at risk.

Delayed postablation imaging, obtained in the majority of subjects, showed a central T2-hypointense nodule circumscribed by T2 hyperintensity. These findings are consistent with a parenchymal ablation cavity (encephalomalacia) around the central involuting CCM. No subject showed post-operative evidence of CCM growth or hemorrhage. Indeed, histopathologic examination of an ablated CCM found no remaining pathognomonic features. Together, these findings support the notion that SLA can obliterate structural and cellular features of CCMs.

Our observations may not necessarily apply to all cavernous malformations. For instance, a CCM can come to clinical attention not from epilepsy, but from a natural history of hemorrhage and growth, causing headaches or neurologic deficits. Subcortical, brainstem, and spinal cord cavernous malformations provide additional management challenges with respect to the sensitivity of surrounding neural structures. In addition, familial CCMs may present with multiple lesions, varied neurologic sequelae, and greater risk of recurrence. None of the subjects in this series had a personal history of symptomatic bleeding. Thus, greater caution before using SLA for a deep-seated CCM, multifocal or familial CCM, and/or lesions with aggressive natural histories may be warranted, especially because the tissue temperatures achieved during laser interstitial thermal therapy are well below those achieved by direct current electrocautery instruments and unlikely to provide direct hemostasis.⁴⁶ In patients presenting with acute hemorrhage and neurologic deficits related to mass effect, strong consideration should still be given to open microsurgery.

5 | CONCLUSION

Real-time MR thermography-guided SLA is a minimally invasive alternative to open microsurgery that can

definitively ablate both the CCM and associated epileptic cortex while potentially minimizing collateral injury to off-target structures. SLA of CCMs is feasible, and when compared to open surgery, may be as effective for epilepsy and as tolerable or more tolerable. SLA thus holds promise as a first-line, minimally invasive therapy for the management of epilepsy associated with CCMs, but larger case-controlled long-term studies are needed.

ACKNOWLEDGMENTS

We thank Gloria Novak for clinical research coordination and Robert Smith for coordinating MRI scan acquisition. This study was funded in part by to DLD (A1225797 BFN:1056035), the NIH/NINDS to DLD (R01NS088748, K02NS070960), and a Shared Instrumentation Grant (S10: Grant 1@100D016413-01) to the Emory University Center for Systems Imaging Core.

DISCLOSURE OF CONFLICT OF INTEREST

JTW and REG serve as consultants to Medtronic, Inc., and receive compensation for these services. DLD has had an industry-sponsored research grant from Medtronic, Inc., which develops products related to the research described in this article. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict of interest policies. The remaining authors have nothing to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

ORCID

Jon T. Willie  <https://orcid.org/0000-0001-9565-4338>

Matthew A. Stern  <https://orcid.org/0000-0001-8278-6374>

REFERENCES

1. Raychaudhuri R, Batjer HH, Awad IA. Intracranial cavernous angioma: a practical review of clinical and biological aspects. *Surg Neurol*. 2005;63:319–28.
2. Rosenow F, Alonso-Vanegas MA, Baumgartner C, et al. Cavernoma-related epilepsy: review and recommendations for management - Report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia*. 2013;54:2025–35.
3. Poorthuis MHF, Klijn CJM, Algra A, et al. Treatment of cerebral cavernous malformations: a systematic review and meta-regression analysis. *J Neurol Neurosurg Psychiatry*. 2014;85:1319–23.
4. Baumann CR, Schuknecht B, Lo Russo G, et al. Seizure outcome after resection of cavernous malformations is better when surrounding hemosiderin-stained brain also is removed. *Epilepsia*. 2006;47:563–6.
5. von der Brelie C, von Lehe M, Raabe A, et al. Surgical resection can be successful in a large fraction of patients with drug-resistant epilepsy associated with multiple cerebral cavernous malformations. *Neurosurgery*. 2014;74:147–53. discussion 153.
6. Kim W, Stramotas S, Choy W, et al. Prognostic factors for post-operative seizure outcomes after cavernous malformation treatment. *J Clin Neurosci*. 2011;18:877–80.
7. Horne MA, Flemming KD, Su IC, et al. Clinical course of untreated cerebral cavernous malformations: a meta-analysis of individual patient data. *Lancet Neurol*. 2016;15:166–73.
8. Steiger HJ, Markwalder TM, Reulen HJ. Clinicopathological relations of cerebral cavernous angiomas — observations in 11 cases. *Neurosurgery*. 1987;21:879–84.
9. Awad I, Jabbour P. Cerebral cavernous malformations and epilepsy. *Neurosurg Focus*. 2006;21:e7.
10. Chang EF, Gabriel RA, Potts MB, et al. Supratentorial cavernous malformations in eloquent and deep locations: surgical approaches and outcomes Clinical article. *J Neurosurg*. 2011;114:814–27.
11. Moran NF, Fish DR, Kitchen N, et al. Supratentorial cavernous haemangiomas and epilepsy: a review of the literature and case series. *J Neurol Neurosurg Psychiatry*. 1999;66:561–8.
12. McNichols RJ, Gowda A, Kangasniemi M, et al. MR thermometry-based feedback control of laser interstitial thermal therapy at 980 nm. *Lasers Surg Med*. 2004;34:48–55.
13. Willie JT, Laxpati NG, Drane DL, et al. Real-time magnetic resonance-guided stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. *Neurosurgery*. 2014;74:569–84; discussion 584–565.
14. Curry DJ, Gowda A, McNichols RJ, et al. MR-guided stereotactic laser ablation of epileptogenic foci in children. *Epilepsy Behav*. 2012;24:408–14.
15. Schwarzmaier H-J, Eickmeyer F, von Tempelhoff W, et al. MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: preliminary results in 16 patients. *Eur J Radiol*. 2006;59:208–15.
16. Carpentier A, Chauvet D, Reina V, et al. MR-guided laser-induced thermal therapy (LITT) for recurrent glioblastomas. *Lasers Surg Med*. 2012;44:361–8.
17. Tovar-Spinoza Z, Carter D, Ferrone D, et al. The use of MRI-guided laser-induced thermal ablation for epilepsy. *Childs Nerv Syst*. 2013;29:2089–94.
18. Rao MS, Hargreaves EL, Khan AJ, et al. Magnetic resonance-guided laser ablation improves local control for postradiosurgery recurrence and/or radiation necrosis. *Neurosurgery*. 2014;74:658–67.
19. Hawasli AH, Bagade S, Shimony JS, et al. Magnetic resonance imaging-guided focused laser interstitial thermal therapy for intracranial lesions: single-institution series. *Neurosurgery*. 2013;73:1007–17.
20. Drane D, Loring D, Voets N, et al. Temporal lobe epilepsy surgical patients undergoing MRI-guided stereotactic laser ablation exhibit better episodic memory outcome as compared to standard surgical approaches. *Epilepsy Curr*. 2014;14:468–9. B.407.
21. Gross RE, Stern MA, Willie JT, et al. Stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy. *Ann Neurol*. 2018;83:575–87.
22. Drane DL, Loring DW, Voets NL, et al. Better object recognition and naming outcome with MRI-guided stereotactic laser amygdalohippocampotomy for temporal lobe epilepsy. *Epilepsia*. 2015;56:101–13.

23. McCracken DJ, Willie JT, Fernald BA, et al. Magnetic resonance thermometry-guided stereotactic laser ablation of cavernous malformations in drug-resistant epilepsy: imaging and clinical results. *Oper Neurosurg* (Hagerstown). 2016;12:39–48.
24. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58:522–30.
25. Willie JT, Tung JK, Gross RE. Chapter 16 - MRI-Guided Stereotactic Laser Ablation A2. In: Golby AJ, editor. *Image-guided neurosurgery*. Boston, MA: Academic Press, 2015; p. 375–403.
26. Engel J, Van Ness PC, Rasmussen TB, et al. Outcome with Respect to Epileptic Seizures. In: *Surgical Treatment of the Epilepsies*, 2nd edn. Engel J (ed). New York: Raven Press; 1993: pp. 609–21.
27. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 Through 1967. *Epilepsia*. 1975;16:1–66.
28. Lewis EC, Weil AG, Duchowny M, et al. MR-guided laser interstitial thermal therapy for pediatric drug-resistant lesional epilepsy. *Epilepsia*. 2015;56:1590–8.
29. Jethwa PR, Barrese JC, Gowda A, et al. Magnetic resonance thermometry-guided laser-induced thermal therapy for intracranial neoplasms: initial experience. *Neurosurgery*. 2012;71:133–44.
30. Hawasli AH, Ray WZ, Murphy RKJ, et al. Magnetic resonance imaging-guided focused laser interstitial thermal therapy for subinsular metastatic adenocarcinoma: technical case report. *Neurosurgery*. 2012;70:332–8.
31. Jethwa PR, Lee JH, Assina R, et al. Treatment of a supratentorial primitive neuroectodermal tumor using magnetic resonance-guided laser-induced thermal therapy. *J Neurosurg Pediatr*. 2011;8:468–75.
32. Sloan AE, Ahluwalia MS, Valerio-Pascua J, et al. Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma Clinical article. *J Neurosurg*. 2013;118:1202–19.
33. Leonardi MA, Lumenta CB. Stereotactic guided laser-induced interstitial thermotherapy (SLITT) in gliomas with intraoperative morphologic monitoring in an open MR: clinical experience. *Minim Invasive Neurosurg*. 2002;45:201–7.
34. Esquenazi Y, Kalamangalam GP, Slater JD, et al. Stereotactic laser ablation of epileptogenic periventricular nodular heterotopia. *Epilepsy Res*. 2014;108:547–54.
35. Akers A, Al-Shahi SR, AAwad I, et al. Synopsis of guidelines for the clinical management of cerebral cavernous malformations: Consensus recommendations based on systematic literature review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. *Neurosurgery*. 2017;80:665–80.
36. Jehi LE, Palmini A, Aryal U, et al. Cerebral cavernous malformations in the setting of focal epilepsies: pathological findings, clinical characteristics, and surgical treatment principles. *Acta Neuropathol*. 2014;128:55–65.
37. Yeon JY, Kim JS, Choi SJ, et al. Supratentorial cavernous angiomas presenting with seizures: surgical outcomes in 60 consecutive patients. *Seizure*. 2009;18:14–20.
38. Hsu PW, Chang CN, Tseng CK, et al. Treatment of epileptogenic cavernomas: surgery versus radiosurgery. *Cerebrovasc Dis*. 2007;24:116–20; discussion 121.
39. Bartolomei F, Regis J, Kida Y, et al. Gamma Knife radiosurgery for epilepsy associated with cavernous hemangiomas: a retrospective study of 49 cases. *Stereotact Funct Neurosurg*. 1999;72:22–8.
40. Cappabianca P, Alfieri A, Maiuri F, et al. Supratentorial cavernous malformations and epilepsy: seizure outcome after lesionectomy on a series of 35 patients. *Clin Neurol Neurosurg*. 1997;99:179–83.
41. Zanello M, Wager M, Corns R, et al. Resection of cavernous angioma located in eloquent areas using functional cortical and subcortical mapping under awake conditions. Outcomes in a 50-case multicentre series. *Neurochirurgie*. 2017;63:219–26.
42. Delev D, Oehl B, Steinhoff BJ, et al. Surgical treatment of extratemporal epilepsy: results and prognostic factors. *Neurosurgery*. 2018;13:e0196274.
43. Kondziolka D, Flickinger JC, Lunsford LD. Stereotactic radiosurgery for epilepsy and functional disorders. *Neurosurg Clin N Am*. 2013;24:623–32.
44. Barbaro NM, Quigg M, Ward MM, et al. Radiosurgery versus open surgery for mesial temporal lobe epilepsy: The randomized, controlled ROSE trial. *Epilepsia*. 2018;59:1198–207.
45. Quigg M, Harden C. Minimally invasive techniques for epilepsy surgery: stereotactic radiosurgery and other technologies. *J Neurosurg*. 2014;121(Suppl):232–40.
46. Consiglieri GD, Killory BD, Germain RS, et al. Utility of the CO2 laser in the microsurgical resection of cavernous malformations. *World Neurosurg*. 2013;79:714–8.

How to cite this article: Willie JT, Malcolm JG, Stern MA, et al. Safety and effectiveness of stereotactic laser ablation for epileptogenic cerebral cavernous malformations. *Epilepsia*. 2019;00:1–13.
<https://doi.org/10.1111/epi.14634>